Built by Scientists. Backed by Clinical Research.

NextEvo was founded by former Johnson & Johnson executives who spent decades developing breakthrough pharmaceutical products — and who saw a CBD industry built almost entirely on marketing rather than science. The problem wasn't CBD itself. The problem was delivery. Oil-based CBD products, which dominate the market, are poorly absorbed by the human body. Most of the CBD in a standard product never reaches the bloodstream. Our founders knew this could be solved — because they had spent careers solving exactly these kinds of drug delivery challenges. The result is SmartSorb™: a patented water-soluble CBD technology validated in peer-reviewed clinical trials. It delivers 6x better absorption and works in as little as 10 minutes — not because we say so, but because the data says so.
 

Our Mission

To apply pharmaceutical-grade science to CBD — and deliver products that actually perform. We believe wellness should be evidence-based, not aspirational. Every NextEvo formula is clinically tested, independently verified, and built to the same standards we held ourselves to in the pharmaceutical industry.

By the Numbers

30+

Patents in drug delivery and pharmaceutical formulation
 

50+ Years

Combined pharmaceutical R&D, clinical development and commercialization
 

Clinical Trials

Peer-reviewed research validating SmartSorb™ absorption and onset superiority

VP of Research & Development

Gerry McNally, Ph.D.

Gerry brings more than 25 years of pharmaceutical R&D leadership to NextEvo, including a career at McNeil Consumer Healthcare and Johnson & Johnson where he led development of some of the most recognized OTC products on the market — including Tylenol® Rapid Release Gels, Imodium® Multi-Symptom Relief, and Pepcid® Complete. He holds 30+ patents in drug delivery and pharmaceutical formulation, and was instrumental in several major Rx-to-OTC switches including Pepcid® AC and Zyrtec®. His expertise in bioavailability and novel delivery systems is the foundation of SmartSorb™ technology. Gerry earned his Ph.D. and BSc Honours in Chemistry from University College Dublin.

Chief Medical Officer

David Chernoff, MD

Dr. Chernoff is a molecular diagnostics and biopharmaceutical veteran with more than 25 years of global clinical development experience. He has served as Chief Medical Officer for multiple companies including Adamas Pharmaceuticals, Aquinox, Crescendo Bioscience, Schiff Nutrition, and SetPoint Medical — leading early-stage R&D programs through clinical validation and commercialization. At NextEvo, Dr. Chernoff oversees the clinical research that validates SmartSorb™ technology — providing the peer-reviewed evidence that separates NextEvo from every other CBD brand. His work includes the clinical trials demonstrating 6x superior absorption and 40x faster onset versus oil-based CBD products. Dr. Chernoff is a graduate of Yale University and NYU Grossman School of Medicine, with a specialty interest in anti-inflammatory science.
 

The Science Speaks for Itself

NextEvo is the only CBD brand with this depth of pharmaceutical expertise behind it. See how SmartSorb™ technology works — or explore our product range and experience the difference for yourself.